Progressive Multiple Sclerosis, San Raffaele in Milan to coordinate an international research team
They set themselves a time limit of four years to find effective molecules for the treatment of progressive multiple sclerosis. They are the researchers of the international team coordinated by Gianvito Martino (pictured), Full Professor of Applied Biology at Vita-Salute San Raffaele University in Milan and Honorary Professor at the School of Medicine of Queen Mary University of London.
The project receives “considerable funding” from the International Progressive MS Alliance, an international organization that brings together the major associations of various countries involved in research on progressive multiple sclerosis, including the Italian Multiple Sclerosis Society (AISM).
BRAVEinMS (this is the title of the project, which involves laboratories of excellence from Europe, the U.S. and Canada) aims to bring together the world’s best expertise and the latest bioinformatics and biotechnology techniques to accelerate the discovery of potential drugs against the disease, able to protect nerve cells and promote myelin repair.
As well as San Raffaele Hospital, the international consortium involves the University of Milan, Italy’s National Research Council (CNR), Italy’s National Institute of Health (ISS), IRBM in Pomezia, UCSF in San Francisco, Sapienza University of Rome, McGill University of Montreal, Pierre and Marie Curie University of Paris, University of Mainz, University of Münster, and University of Düsseldorf.
“It is a fundamental step in the right direction – said Professor Martino –: research that matters is no longer, or perhaps has never been, restricted within national boundaries; it is not the research of a group, a laboratory, nor of a single scientist, but belongs to the whole scientific community; we need more cooperation, beyond disciplinary boundaries that are becoming more and more blurred, and beyond geographical boundaries: this is the only way to make progress in the knowledge of diseases and develop effective therapies”.